Artificial intelligence is reshaping how new medicines are found, and two companies are taking notably different routes to get there.
According to NAI500, Eli Lilly and Twist Bioscience are charting two distinct paths to industrialize AI-driven drug discovery. The report frames the moment as AI "rewriting" the way drugs are discovered, with each company representing a different strategy for turning that promise into a repeatable, scalable process rather than a one-off breakthrough.
The key idea is divergence. Rather than the industry converging on a single playbook, NAI500 describes Eli Lilly — one of the world's largest pharmaceutical firms — and Twist Bioscience pursuing separate approaches to building AI discovery into an industrial pipeline. The framing suggests there is no consensus yet on the "right" way to apply AI to the long, expensive work of finding and developing new treatments.
The source provided here is a single news summary, so the specific technical details of each company's approach — the exact tools, timelines, or results — are not laid out in the material available. What is clear is the broader narrative: AI is moving from experimental promise toward something companies are trying to operationalize at scale, and major players are betting on different models for how to do it.
Why it matters: drug discovery is famously slow, costly, and failure-prone, so how the industry's biggest names choose to deploy AI could shape which new medicines reach patients, how fast, and at what cost — making the choice between these competing paths something worth watching closely.